Cargando…
Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease
BACKGROUND AND OBJECTIVES: Vascular disease is a known risk factor for Alzheimer’s disease (AD). Endothelial dysfunction has been linked to reduced cerebral blood flow. Endothelial nitric oxide synthase pathway (eNOS) upregulation is known to support endothelial health. This single-center, proof-of-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482313/ https://www.ncbi.nlm.nih.gov/pubmed/36115980 http://dx.doi.org/10.1186/s13195-022-01076-7 |
_version_ | 1784791429461049344 |
---|---|
author | Degrush, Elizabeth Shazeeb, Mohammed Salman Drachman, David Vardar, Zeynep Lindsay, Clifford Gounis, Matthew J. Henninger, Nils |
author_facet | Degrush, Elizabeth Shazeeb, Mohammed Salman Drachman, David Vardar, Zeynep Lindsay, Clifford Gounis, Matthew J. Henninger, Nils |
author_sort | Degrush, Elizabeth |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Vascular disease is a known risk factor for Alzheimer’s disease (AD). Endothelial dysfunction has been linked to reduced cerebral blood flow. Endothelial nitric oxide synthase pathway (eNOS) upregulation is known to support endothelial health. This single-center, proof-of-concept study tested whether the use of three medications known to augment the eNOS pathway activity improves cognition and cerebral blood flow (CBF). METHODS: Subjects with mild AD or mild cognitive impairment (MCI) were sequentially treated with the HMG-CoA reductase synthesis inhibitor simvastatin (weeks 0–16), l-arginine (weeks 4–16), and tetrahydrobiopterin (weeks 8–16). The primary outcome of interest was the change in CBF as measured by MRI from baseline to week 16. Secondary outcomes included standard assessments of cognition. RESULTS: A total of 11 subjects were deemed eligible and enrolled. One subject withdrew from the study after enrollment, leaving 10 subjects for data analysis. There was a significant increase in CBF from baseline to week 8 by ~13% in the limbic and ~15% in the cerebral cortex. Secondary outcomes indicated a modest but significant increase in the MMSE from baseline (24.2±3.2) to week 16 (26.0±2.7). Exploratory analysis indicated that subjects with cognitive improvement (reduction of the ADAS-cog 13) had a significant increase in their respective limbic and cortical CBF. CONCLUSIONS: Treatment of mild AD/MCI subjects with medications shown to augment the eNOS pathway was well tolerated and associated with modestly increased cerebral blood flow and cognitive improvement. TRIAL REGISTRATION: This study is registered in https://www.clinicaltrials.gov; registration identifier: NCT01439555; date of registration submitted to registry: 09/23/2011; date of first subject enrollment: 11/2011. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01076-7. |
format | Online Article Text |
id | pubmed-9482313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94823132022-09-18 Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease Degrush, Elizabeth Shazeeb, Mohammed Salman Drachman, David Vardar, Zeynep Lindsay, Clifford Gounis, Matthew J. Henninger, Nils Alzheimers Res Ther Research BACKGROUND AND OBJECTIVES: Vascular disease is a known risk factor for Alzheimer’s disease (AD). Endothelial dysfunction has been linked to reduced cerebral blood flow. Endothelial nitric oxide synthase pathway (eNOS) upregulation is known to support endothelial health. This single-center, proof-of-concept study tested whether the use of three medications known to augment the eNOS pathway activity improves cognition and cerebral blood flow (CBF). METHODS: Subjects with mild AD or mild cognitive impairment (MCI) were sequentially treated with the HMG-CoA reductase synthesis inhibitor simvastatin (weeks 0–16), l-arginine (weeks 4–16), and tetrahydrobiopterin (weeks 8–16). The primary outcome of interest was the change in CBF as measured by MRI from baseline to week 16. Secondary outcomes included standard assessments of cognition. RESULTS: A total of 11 subjects were deemed eligible and enrolled. One subject withdrew from the study after enrollment, leaving 10 subjects for data analysis. There was a significant increase in CBF from baseline to week 8 by ~13% in the limbic and ~15% in the cerebral cortex. Secondary outcomes indicated a modest but significant increase in the MMSE from baseline (24.2±3.2) to week 16 (26.0±2.7). Exploratory analysis indicated that subjects with cognitive improvement (reduction of the ADAS-cog 13) had a significant increase in their respective limbic and cortical CBF. CONCLUSIONS: Treatment of mild AD/MCI subjects with medications shown to augment the eNOS pathway was well tolerated and associated with modestly increased cerebral blood flow and cognitive improvement. TRIAL REGISTRATION: This study is registered in https://www.clinicaltrials.gov; registration identifier: NCT01439555; date of registration submitted to registry: 09/23/2011; date of first subject enrollment: 11/2011. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01076-7. BioMed Central 2022-09-17 /pmc/articles/PMC9482313/ /pubmed/36115980 http://dx.doi.org/10.1186/s13195-022-01076-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Degrush, Elizabeth Shazeeb, Mohammed Salman Drachman, David Vardar, Zeynep Lindsay, Clifford Gounis, Matthew J. Henninger, Nils Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease |
title | Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease |
title_full | Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease |
title_fullStr | Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease |
title_full_unstemmed | Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease |
title_short | Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease |
title_sort | cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in alzheimer’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482313/ https://www.ncbi.nlm.nih.gov/pubmed/36115980 http://dx.doi.org/10.1186/s13195-022-01076-7 |
work_keys_str_mv | AT degrushelizabeth cumulativeeffectofsimvastatinlarginineandtetrahydrobiopterinoncerebralbloodflowandcognitivefunctioninalzheimersdisease AT shazeebmohammedsalman cumulativeeffectofsimvastatinlarginineandtetrahydrobiopterinoncerebralbloodflowandcognitivefunctioninalzheimersdisease AT drachmandavid cumulativeeffectofsimvastatinlarginineandtetrahydrobiopterinoncerebralbloodflowandcognitivefunctioninalzheimersdisease AT vardarzeynep cumulativeeffectofsimvastatinlarginineandtetrahydrobiopterinoncerebralbloodflowandcognitivefunctioninalzheimersdisease AT lindsayclifford cumulativeeffectofsimvastatinlarginineandtetrahydrobiopterinoncerebralbloodflowandcognitivefunctioninalzheimersdisease AT gounismatthewj cumulativeeffectofsimvastatinlarginineandtetrahydrobiopterinoncerebralbloodflowandcognitivefunctioninalzheimersdisease AT henningernils cumulativeeffectofsimvastatinlarginineandtetrahydrobiopterinoncerebralbloodflowandcognitivefunctioninalzheimersdisease |